OPKO Health (NASDAQ:OPK) Rating Lowered to “Sell” at Wall Street Zen

OPKO Health (NASDAQ:OPK) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

OPK has been the topic of a number of other reports. JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OPKO Health has a consensus rating of “Hold” and an average price target of $2.28.

OPKO Health Stock Down 0.7%

OPK opened at $1.38 on Friday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -5.52 and a beta of 1.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70. The firm’s fifty day moving average is $1.40 and its 200 day moving average is $1.38. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. The business had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative return on equity of 13.67% and a negative net margin of 28.10%.The business’s quarterly revenue was down 12.6% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share. On average, sell-side analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 580,000 shares of the stock in a transaction on Friday, November 21st. The stock was acquired at an average price of $1.33 per share, for a total transaction of $771,400.00. Following the completion of the transaction, the chief executive officer directly owned 216,706,448 shares of the company’s stock, valued at $288,219,575.84. This trade represents a 0.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired a total of 1,843,300 shares of company stock worth $2,421,491 in the last three months. 49.69% of the stock is owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Several institutional investors have recently made changes to their positions in OPK. Brighton Jones LLC boosted its holdings in shares of OPKO Health by 29.1% in the second quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 8,775 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of OPKO Health by 4.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock worth $262,000 after buying an additional 8,954 shares during the period. 360 Financial Inc. grew its position in shares of OPKO Health by 12.0% during the 2nd quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company’s stock worth $117,000 after buying an additional 9,500 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of OPKO Health by 11.2% during the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 13,912 shares during the period. Finally, Caprock Group LLC bought a new stake in shares of OPKO Health in the third quarter valued at about $26,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.